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Escalation of liPid‑lOwering 
therapy in patientS wiTh vascular 
disease receiving HIGH‑intensity 
statins: the retrospective 
POST‑HIGH study
Jaehyung Ha1,3, Bom Lee1,3, Jung Mi Park2, Moonjong Kang2, Jaewon Oh1, Chan Joo Lee1, 
Sungha Park1, Seok‑Min Kang1 & Sang‑Hak Lee 1*
In this retrospective study, we investigated whether lipid‑lowering therapy (LLT) escalation has clinical 
benefits in patients with atherosclerotic cardiovascular disease (ASCVD) and low‑density lipoprotein 
cholesterol (LDL‑C) levels of 55–99 mg/dL (1.4–2.6 mmol/L), post high‑intensity. Out of 6317 Korean 
patients screened in 2005–2018, 1159 individuals with ASCVD and LDL‑C levels of 55–99 mg/dL after 
statin use equivalent to 40 mg atorvastatin were included. After 1:2 propensity score matching, 492 
patients (164 with LLT escalation, 328 controls without LLT escalation) were finally analysed. Primary 
outcome variables were major adverse cardiovascular and cerebrovascular events (MACCE) and all‑
cause death. At median follow‑up (1.93 years), the escalation group had a lower MACCE rate (1.72 
vs. 3.38 events/100 person‑years; hazard ratio [HR] 0.34, 95% confidence interval [CI] 0.14–0.83; 
p = 0.018) than the control group. The incidence of all‑cause death (0.86 vs. 1.02 events/100 person‑
years; HR 0.58, 95% CI 0.15–2.19; p = 0.42) and each MACCE component did not differ between 
groups. Kaplan–Meier curves exhibited lower risk of MACCE in the escalation group (HR 0.36, 95% CI 
0.12–0.97; p = 0.040) but a difference not statistically significant in all‑cause death (HR 0.30, 95% CI 
0.04–2.48; p = 0.26). LLT escalation was associated with reduced cardiovascular risk, supporting more 
aggressive LLT in this population.
The principles of contemporary lipid-lowering therapy (LLT) are based on a volume of evidence showing that 
stronger LLT can yield greater absolute benefits, particularly in patients with high cardiovascular  risk1. When 
a patient carries a very high risk of conditions such as atherosclerotic cardiovascular disease (ASCVD), the 
majority of the latest guidelines recommend a reduction in the low-density lipoprotein cholesterol (LDL-C) 
levels to < 70 mg/dL (1.8 mmol/L)2 or < 55 mg/dL (1.4 mmol/L)3 with a 50% simultaneous reduction in the levels. 
However, evidence showing the benefits of a further reduction in lipid concentration in patients with LDL-C 
levels of 55 to 99 mg/dL (1.4–2.6 mmol/L), particularly in those with levels < 70 mg/dL, is scarce.
Despite the evidence and recommendations mentioned above, high-intensity statins and dose escalation are 
used less often than needed in real-world practice, as shown in many reports  worldwide4–6. Moreover, suboptimal 
lipid lowering by insufficient drug doses may elevate the future cardiovascular  risk7.
It has been reported that the reduction in cholesterol levels despite the use of the same statin doses is some-
times greater in East Asians than in other  ethnicities8. In addition, a low-intensity statin regimen showed outcome 
benefits in Japanese  individuals9, whereas a similar regimen in a study with participants consisting mostly of 
Caucasians or those of African descendants did  not10. In this regard, East Asians are considered more sensi-
tive to lipid-lowering drugs. Therefore, physicians managing such populations are hesitant to treat them with 
high-intensity regimens. Particularly, physicians may be less open to escalating the LLT intensity when the post-
treatment LDL-C levels are 55 to 99 mg/dL (1.4–2.6 mmol/L), slightly above the current target levels. However, 
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the availability of research data supporting decision-making on pharmacotherapy in such clinical settings is 
highly limited.
The aim of this POST-HIGH (Escalation of lipid-lOwering therapy in patientS wiTh vascular disease and 
HIGH-intensity statins) study was to investigate whether escalation of LLT intensity has clinical benefits in 1159 
Koreans with ASCVD and LDL-C levels of 55–99 mg/dL (1.4–2.6 mmol/L) despite the use of statins with an 
efficacy similar to atorvastatin 40 mg. We used propensity score matching to select patients for the LLT escalation 
and control groups and compared clinical outcomes between the groups.
Methods
Study population. The Institutional Review Board of Severance Hospital, Seoul, Korea, approved this study 
(No. 4-2020-476). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. 
The subjects were selected from patients who visited the Division of Cardiology, Severance Hospital, Seoul, 
Korea, between 2005 and 2018. The need for informed consent from the subjects themselves was waived for the 
following reasons: (1) the research involved no more than minimal risk to the subjects; (2) the waiver did not 
adversely affect the rights and welfare of the subjects. The waiver was approved by the Institutional Review Board 
mentioned above.
Consecutive patients who visited the outpatient clinic during the study period were initially screened. The 
inclusion criteria were as follows: a diagnosis of ASCVD, use of high-intensity statins equivalent to atorvasta-
tin 40 mg, LDL-C levels of 55–99 mg/dL (1.4–2.6 mmol/L) assessed at least 2 months post-treatment with the 
aforementioned regimen, and a regular follow-up of ≥ 12 months with laboratory work-up. ASCVD included 
coronary artery disease, ischaemic stroke, peripheral artery disease, carotid artery disease, and aortic disease. 
Patients meeting all the inclusion criteria were eligible for the study. We excluded patients who used LLT incon-
sistently or with inconsistent intensity throughout the follow-up period. We defined inconsistent LLT use as 
prescription of LLT agents for a period < 80% of follow-up duration. Inconsistent LLT intensity was defined as a 
change in the LLT agent to different intensity categories during the follow-up and the treatment duration with 
the mainly-prescribed LLT agent comprising < 80% of total prescription period.
To reduce the impact of selection bias and potential confounders, we conducted a 1:2 propensity score match-
ing of patients with an escalated intensity of LLT (escalation group) versus those with a maintained intensity of 
LLT (control group). Details on the method for matching is described in the statistical analysis section.
Study protocol. This was a retrospective, propensity score-matched study. Clinical data including demo-
graphic variables and medical history were obtained by trained interviewers. Blood samples were collected after 
a 12-h fast and analysed by the local laboratory, which is certified by the Korean Society of Laboratory Medicine. 
The data derived from these samples were used retrospectively for this study. All patients received standard 
medical therapies at the physicians’ discretion. LLT intensity and titration were decided based on domestic-8 
or major international  guidelines11–13 frequently followed during the study period. For example, most of the 
guidelines that physicians referred recommended < 70 mg/dL (1.8 mmol/L) as an LDL-C target for individuals 
with ASCVD. The statin intensity was defined according to the 2013 American College of Cardiology/American 
Heart Association  guidelines13.
Patients were followed-up in the outpatient clinic every 3–6 months; they underwent lipid profile examina-
tion every 3–12 months. The baseline LDL-C level was defined as the level under treatment with high-intensity 
statins before LLT escalation. The follow-up LDL-C level was determined as the average level examined during 
the follow-up period. The clinical outcome data were obtained by reviewing the medical records and data from 
the Korean Statistical Information Service. The primary outcome variables were as follows: the rates of major 
adverse cardiovascular and cerebrovascular events (MACCE) and all-cause death. MACCE was defined as the 
composite of cardiovascular death, nonfatal myocardial infarction, percutaneous coronary intervention, coronary 
artery bypass grafting, and nonfatal ischaemic stroke. Cardiovascular death was defined as death resulting from 
cardiovascular causes, including acute myocardial infarction, sudden cardiac death, heart failure, or  stroke14. 
Myocardial infarction was defined according to the following conditions: clinical symptoms, ECG changes, or 
abnormal imaging findings suggestive of myocardial infarction, along with an increase of creatine kinase myo-
cardial band fraction above the upper limit of normal or an increase of troponin-T/troponin-I above the  99th 
percentile of the upper limit of  normal15. Percutaneous coronary intervention or coronary artery bypass grafting 
were chosen based on (1) diameter stenosis > 50% according to quantitative coronary angiographic analysis with 
positive stress test results, or (2) diameter stenosis > 70%. Ischemic stroke was detected by new neurological deficit 
and confirmed using a neurological examination and imaging work-up. When outcome data were collected, the 
occurrence of events were confirmed according to these definitions. The secondary outcome variables were the 
individual components of MACCE.
Statistical analysis. Continuous variables were tested for normality using the Shapiro–Wilk normality 
test. Variables with normal distribution are presented as means ± standard deviation, and non-normally distrib-
uted variables are presented as median (interquartile range: IQR). Categorical data are presented as frequencies 
and percentages. Clinical and laboratory data were compared using the chi-square test.
Propensity scores were estimated with a multivariable logistic regression including age, sex, hypertension, 
diabetes mellitus, chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73  m2), atrial fibril-
lation, acute coronary syndrome, body mass index, number of diseased coronary arteries, and LDL-C levels. 
Following the estimation of score, patients with or without LLT escalation were matched using 1:2 nearest 
neighbour matching with a caliper distance set at 0.2 standard deviation of the logit of score. The matching and 
LLT escalation effect estimation were conducted with the “Matching” package for R. Post-matching validation 
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was performed according to the standard mean difference of all baseline covariates using a threshold of 0.1 to 
indicate imbalance.
After propensity score matching, McNemar’s test for categorical variables was performed to evaluate asso-
ciations. Continuous variables with non-normal distribution were compared using Wilcoxon signed-rank test, 
whereas paired t-test was applied to compare normally distributed variables. Conditional logistic regression 
was utilized to identify the effect of LLT escalation in consideration of propensity-matched pairs. The cumula-
tive survival curves for each group were plotted using the Kaplan–Meier method and compared using stratified 
Cox’s proportional hazard regression model. All analyses used two-tailed tests with a significance level of 0.05. 
The statistical software R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for 
the analyses.
Results
Clinical characteristics. Of the 6317 Korean patients screened, 1159 individuals who met the inclusion 
criteria with LDL-C levels of 55 to 99 mg/dL (1.4 to 2.6 mmol/L) after statin therapy equivalent to atorvastatin 
40 mg/day were enrolled. Among them, 236 patients were prescribed escalated LLT (escalation group) and 923 
patients were not (control group). After propensity score matching, 492 patients (164 and 328 in the escalation 
and control groups, respectively) were finally analysed (Fig.  1). The mean age of the total study sample was 
59 years, and 377 patients (77%) were men. Most (92%) individuals were diagnosed with coronary artery disease 
and the median LDL-C level at enrolment were 80 and 79 mg/dL (2.04 and 2.02 mmol/L) in the escalation and 
control groups, respectively. The ranges of levels were 55–99 mg/dL (1.42  .56 mmol/L) (Table 1).
In the escalation group, 55% of patients received atorvastatin 40 mg/ezetimibe 10 mg or a similar lipid-
lowering regimen and 39% of patients were treated with atorvastatin 20 mg/ezetimibe 10 mg or its equivalent. 
Detailed information on the equivalent regimens is described in the footnote of Table 2. The majority (76%) of 
the control group was prescribed rosuvastatin 20 mg and 21% of the same group received atorvastatin 40 mg 
(Table 2).
Clinical outcomes. The patients were followed-up for a median period of 1.93 years. The median follow-up 
LDL-C levels were 65 and 74 mg/dL (1.68 and 1.91 mmol/L) in the escalation and control groups, respectively 
(p < 0.001). The ranges of levels were 35–111 mg/dL (0.91–2.87 mmol/L) and 31–144 mg/dL (0.80–4.03 mmol/L) 
in each group, respectively. The percentage change in the levels was higher in the escalation group (− 20.9 [− 34.3, 
− 6.7]% and − 6.3 [− 16.7, 6.8]%, respectively, p < 0.001) (Table 1). During the follow-up, the escalation group 
had significantly lower rates of MACCE (1.72 vs 3.38 events/100 person-years; hazard ratio [HR] 0.34, 95% con-
fidence interval [CI] 0.14–0.83; p = 0.018) than the control group. The incidence of all-cause death between the 
two groups did not differ (0.86 vs 1.02 events/100 person-years; HR 0.58, 95% CI 0.15–2.19; p = 0.42) (Table 3). 
The Kaplan–Meier curves exhibited a lower risk of MACCE in the escalation group (HR 0.36, 95% CI 0.13–0.94; 
p = 0.040), whereas the difference in all-cause death was not significant (HR 0.30, 95% CI 0.04–2.48; p = 0.26) 
(Fig. 2). Although the rate of percutaneous coronary intervention was numerically lower in the escalation group, 
the difference was not significant. Other components of MACCE did not differ between the two groups (Table 3).
Figure 1.  Flowchart of patient inclusion. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density 
lipoprotein cholesterol; LLT: lipid-lowering therapy.
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Table 1.  Characteristics of the matched study population. Each value is presented as mean ± standard 
deviation or number (%); LDL-C, low-density lipoprotein cholesterol.
Escalation (n = 164) Control (n = 328) p
Age, years 59.5 ± 10.0 58.8 ± 10.6 0.50



































Acute coronary syndrome 78 (47.6) 156 (47.6)  > 0.99
Body mass index, kg/m2 25.0 (23.4, 26.9) 24.7 (23.2, 26.9) 0.62

















80 (74, 89) (2.07 [1.91, 2.30] mmol/L)
55–98 (1.42–2.53 mmol/L)




65 (54, 73) (1.68 [1.40, 1.89] mmol/L)
35–115 (0.91–2.97 mmol/L)
74 (65, 83) (1.91 [1.68, 2.15] mmol/L)
31–144 (0.80–3.72 mmol/L)  < 0.001
Percent change







Table 2.  Lipid-lowering regimen used in each group. Each value is presented as number (%); a : atorvastatin 
10 mg/ezetimibe 10 mg, rosuvastatin 5 mg/ezetimibe 10 mg, simvastatin 20 mg/ezetimibe 10 mg, pitavastatin 
2 mg/ezetimibe 10 mg; b : rosuvastatin 10 mg/ezetimibe 10 mg, simvastatin 40 mg/ezetimibe 10 mg, 
pitavastatin 4 mg/ezetimibe 10 mg. c : rosuvastatin 20 mg/ezetimibe 10 mg.
Escalation (n = 164) Control (n = 328)
Atorvastatin 40 mg – 68 (20.7)
Rosuvastatin 20 mg – 249 (75.9)
Simvastatin 10 mg/ezetimibe 10 mg – 11 (3.4)
Atorvastatin 80 mg or regimen with similar  efficacya 8 (4.9) –
Atorvastatin 20 mg/ezetimibe 10 mg or regimen with similar  efficacyb 64 (39.0) –
Atorvastatin 40 mg/ezetimibe 10 mg or regimen with similar  efficacyc 92 (55.1) –
Table 3.  Incidence of events in each group. HR, hazard ratio; CI, confidence interval; MACCE, major adverse 
cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft.
Number of events 
(events/100 person-
year)





MACCE 6 (1.72) 33 (3.38) 0.34 (0.14, 0.83) 0.018
Cardiovascular death 0 (0) 1 (0.10) – –
Myocardial infarction 0 (0) 4 (0.41) – –
PCI 5 (1.43) 24 (2.46) 0.41 (0.15, 1.08) 0.070
CABG 1 (0.29) 0 (0) – –
Ischaemic stroke 0 (0) 4 (0.41) – –
All-cause death 3 (0.86) 10 (1.02) 0.58 (0.15, 2.19) 0.42
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Discussion
The major findings of this study are as follows: (1) In Korean patients with ASCVD already on high-intensity 
statins but with LDL-C levels of 55 to 99 mg/dL (1.4–2.6 mmol/L), escalation of LLT was associated with remark-
ably reduced cardiovascular risk; (2) The difference in the risk of all-cause death was not statistically different 
between the two groups. To our knowledge, this study is the first to demonstrate the clear benefits of LLT escala-
tion above high-intensity statins compared to maintaining LLT intensity. Notably, our study may help overcome 
the paucity of data regarding this issue. Furthermore, our findings may reassure physicians who are reluctant to 
uptitrate the LLT in patients, especially in East Asians who are already on high-intensity statins.
Our study is the first to show the clinical benefits of very high-intensity LLT mostly with the statin/ezetimibe 
combination. Except for a few cases who escalate LLT to atorvastatin 80 mg, > 95% of the escalation group took 
LLT of statin/ezetimibe combination. In particular, the results were derived from a study on East Asian patients 
in whom this level of LLT has not been well evaluated. Furthermore, the control group in our study used high-
intensity statins, which distinguishes it from that in the IMPROVE-IT  study16. Therefore, our study results 
provide evidence that may help overcome the paucity of data on the superior effect of high-intensity LLT with 
the statin/ezetimibe combination compared to high-intensity statin monotherapy. The only studies that have 
compared the effects of LLT escalation versus controls on high-intensity statins are the  FOURIER17 and ODYS-
SEY OUTCOMES  trials18 with respect to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It 
is worth mentioning that our study analysed the effects of LLT escalation mostly by adding ezetimibe to high-
intensity statins. Although the benefit of ezetimibe has remained uncertain for several  years19, recent clinical 
trials have shown that adding ezetimibe to statin therapy elicited a reduction in cardiovascular events and greater 
coronary plaque  regression16,20,21. In this regard, the latest European guidelines raised the recommendation level 
of ezetimibe in patients who do not achieve LDL-C goal with maximal tolerable dose  statins3.
In the  FOURIER17 or ODYSSEY OUTCOMES  trials18, the effects of PCSK9 inhibitor-based LLT escalation 
were not statistically different between subgroups of high-intensity statins and those of lower-intensity statins. 
However, in the ODYSSEY OUTCOMES  trial18, the risk reduction by LLT escalation was numerically lower in 
those using high-intensity statins. In this regard, we need to further investigate whether the long-term effects of 
LLT escalation are different from the effects of baseline LLT intensity.
The median baseline LDL-C level in our study population was 80 mg/dL (2.07 mmol/L), which was lower than 
that (93 mg/dL [2.40 mmol/L]) in the IMPROVE-IT  study16 or that (92 mg/dL [2.38 mmol/L]) in the  FOURIER17 
or ODYSSEY OUTCOMES  trials18. Particularly, a substantial portion of the population in the present study 
had levels between 55 and 69 mg/dL (1.4 and 1.8 mmol/L). Such individuals were not regarded as mandatory 
candidates for LLT before the release of the 2019 European guidelines on  LLT3. We found that the effect of LLT 
escalation was not different between patients with a baseline LDL-C level of > 70 mg/dL (1.8 mmol/L) and those 
with an LDL-C level of < 70 mg/dL. This suggests that an LDL-C level of < 70 mg/dL, a target until recently, 
may not be sufficient in our study population. This result is in accordance with that of the post hoc analysis of 
the FOURIER trial, which identified that the addition of evolocumab to maximal- or submaximal-dose statins 
induced incremental clinical benefits even in patients with an LDL-C level of < 70 mg/dL22. We had found a simi-
lar result in our earlier study that revealed that statins equivalent or stronger than atorvastatin 20 mg were more 
beneficial than statins of a lower efficacy in Korean patients with stable coronary artery disease and a baseline 
LDL-C level of < 80 mg/dL (2.07 mmol/L)23.
The incidence of all-cause mortality was not different between the two groups in our study. However, the 
all-cause mortality rate was only 1.02/100 person-years in the control group, and it would be difficult to obtain a 
differential benefit with such a low rate by escalating the LLT. Furthermore, because our sample size and follow-
up duration were not determined to reveal mortality difference between the groups, our data on this issue may 
not be a crucial evidence for a negative result. Conversely, in a meta-analysis on the effect of LLT on mortality 
reduction, the effect was greater when the baseline LDL-C level was higher and the effect was uncertain when 
the level of LDL-C was < 100 mg/dL (2.6 mmol/L)24. Thus, it may be difficult to conclude definitively whether 
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LLT escalation to a very high intensity can reduce the mortality risk in patients with higher LDL-C levels than 
those observed in our study sample.
Moreover, all our study participants were Koreans. There have long been controversies on the differential 
safety and optimal dose of statins in Asian patients. The 2018 American guidelines described this issue as follows: 
Japanese people may be sensitive to statin dosing and show a reduced cardiovascular risk with low-intensity 
pravastatin. Individuals of several Asian ethnicities showed higher rosuvastatin plasma levels than those seen 
in Caucasians, and the FDA recommends a lower starting dose in  Asians2. Thus, it is remarkable that we found 
clinical benefits of escalation of LLT above high-intensity statins in a population of East Asians.
Difference of median follow-up LDL-C between the two groups was small in our study. Difference in LDL-C 
between a test and control groups tended to be smaller when we compare higher- and lower intensity LLT groups, 
particularly when baseline LDL-C was low, like in our or the IMPROVE-IT  study16. In contrast, these differ-
ences were greater when baseline LDL-C was higher like the patients enrolled in the TNT  study25. Additionally, 
although the underlying mechanism is not clear, the smaller difference in LDL-C between the study groups could 
cause greater outcome difference in East Asians like in the MEGA  study9. Therefore, the smaller difference in 
LDL-C in our study population with low baseline LDL-C possibly has significant clinical meaning. The hazard 
ratio of 0.36 for MACCE is more dramatic than estimation by major meta-analysis  data1. In addition, it is dif-
ficult to rule out that biases-related to the observation study design could have affected our results. Conversely, 
it is not clear whether cardiovascular risk reduction by equivalent LLT is greater in East Asians than in other 
ethnicities, as trial data are too scarce in East Asians including Koreans. As mentioned above, the MEGA study 
conducted in Japan reported a hazard ratio for cardiovascular events of 0.67, and this corresponded to a much 
larger risk reduction than estimated by 15% additional reduction of LDL-C9. Furthermore, similar results were 
found in the EWTOPIA 75 study performed using ezetimibe in  Japan26. However, it is not clear what underlies 
the greater benefit in our study than estimated.
Nevertheless, our study has some limitations. First, the mean follow-up duration of 1.93 years is relatively 
short. Although LLT escalation has shown a significant differential effect in this duration, it is not clear from 
these results whether the benefit may change in a longer-term follow-up. Second, despite the significant ben-
efits with regard to MACCE, data on drug safety were not available in our study. The availability of safety data 
might have helped in calculating the net benefit of our LLT strategies and strengthened the conclusions. Third, 
the difference in the composite endpoint was driven mostly by different percutaneous coronary interventions. 
Other endpoints occurred too infrequently to help draw any conclusions. Percutaneous coronary intervention 
is regarded as a softer event and more dependent on physician’s discretion than other end points. Nonetheless, 
we provide evidence that will be helpful in these specific conditions when clinical decision-making is commonly 
difficult, and this may be the greatest strength of our study. Fourth, we cannot completely rule out that physicians 
might have considered coronary intervention less in patients under more aggressive LLT. Furthermore, we could 
not correct for the prescriber factor during propensity score matching due to insufficient information. Different 
medical care that is related to prescriber factor might not be fully ruled out.
In conclusion, escalation of LLT was associated with reduced cardiovascular risk in patients with ASCVD 
who are already on high-intensity statins but with LDL-C levels of 55–99 mg/dL. Our results provide evidence 
on the need for more aggressive LLT uptitration in patients in whom high-intensity statins alone were considered 
adequate for treatment.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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